Plamotamab clinical trials
Also written XmAb13676.
How each study uses plamotamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the plamotamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses plamotamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid ArthritisRecruitingPhase 1Xencor, Inc.NCT07230353Written as Plamotamab
- Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesCompletedPhase 1Xencor, Inc.NCT02924402Written as XmAb13676
- Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)TerminatedPhase 2Xencor, Inc.NCT05328102Written as Plamotamab
Codes
What other systems call plamotamab · ClinicalTrials.gg INT015067
- UNII (FDA) 5ENX424FNFPLAMOTAMABOne source FDA
- NCI Thesaurus C130050PlamotamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5ENX424FNF | PLAMOTAMAB | One source FDA |
| NCI Thesaurus | C130050 | Plamotamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.